Based on a comprehensive analysis of our findings regarding disability status and disease worsening, it was found that MS patients carrying heterozygous FV Leiden and FV R2 mutations had a reduced risk of developing advanced disability and were less likely to progress to advanced stages of the disease. The gene discussed is F5; the disease is myeloid sarcoma.